Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A call for change in anticancer drug evaluation

¹Service des Maladies Sanguines et Tumorales, Hôpital Paul Brousse, Villejuif, France.

European Journal of Cancer (Oxford, England : 1990)

|January 1, 1997

Summary

Current cancer drug trials focus on cytotoxicity and tumor shrinkage, missing clinically relevant efficacy measures. New, faster trial designs are needed to bring promising anticancer agents to patients sooner.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

British journal of cancer·2010

Same author

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

British journal of cancer·2008

Same author

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.

British journal of cancer·2007

Same author

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

Same author

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Same author

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004

Area of Science:

Oncology
Clinical Trial Design
Pharmacology

Background:

Current evaluation of anticancer agents heavily relies on cytotoxicity and tumor shrinkage measurements.
These traditional metrics may not fully capture the clinical relevance of drug efficacy.
There's an underutilization of advanced technologies in assessing treatment outcomes.

Purpose of the Study:

To highlight the limitations of current anticancer agent evaluation methods.
To advocate for the adoption of more clinically relevant efficacy measures.
To emphasize the need for flexible and advanced trial designs in oncology.

Main Methods:

Critique of existing methodologies in anticancer drug evaluation.
Discussion on the role of advanced technologies in clinical trials.
Analysis of standardized response criteria and their clinical meaningfulness.

Main Results:

Existing efficacy measures (cytotoxicity, tumor shrinkage) may not align with clinical reality.
Standardized response criteria do not guarantee clinically meaningful outcomes.
Advanced technologies are not being optimally utilized in cancer research.

Conclusions:

A shift towards more flexible and clinically relevant endpoints is necessary for evaluating anticancer agents.
Improved utilization of technology and adaptable trial designs are crucial.
Faster, smaller-scale trials are essential for rapid drug development and patient access.

Related Experiment Videos